Novel enzyme inhibitor paves way for new cancer drug

(The Wistar Institute) Wistar Institute scientists have developed a new type of enzyme inhibitor capable of blocking a biochemical pathway that plays a key role in cancer development.

Based on studies in human melanoma cells, the research paves the way for developing new ways to treat cancer by dampening overactive enzyme activity that leads to uncontrolled tumor growth.

The study shows how small-molecule inhibitors can be designed to target a family of signaling proteins, called phosphatidyl-inositol-3-kinases, or PI3Ks.